Literature DB >> 10434076

Neurofibromatosis in children: the role of the orthopaedist.

A H Crawford1, E K Schorry.   

Abstract

Type 1 neurofibromatosis (NF-1), also known as von Recklinghausen disease, is one of the most common human single-gene disorders, affecting at least 1 million persons throughout the world. It encompasses a spectrum of multifaceted disorders and may present with a wide range of clinical manifestations, including abnormalities of the skin, nervous tissue, bones, and soft tissues. The condition can be conclusively diagnosed when two of seven criteria established by the National Institutes of Health Consensus Development Conference are met. Most children with NF-1 have no major orthopaedic problems. For those with musculoskeletal involvement, the most important issue is early recognition. Spinal deformity, congenital tibial dysplasia (congenital bowing and pseudarthrosis), and disorders of excessive bone and soft-tissue growth are the three types of musculoskeletal manifestations that require evaluation. Statistics gathered from the Cincinnati Children's Hospital Neurofibromatosis Center database show the incidence of spinal deformity in children with NF-1 to be 23.6%; pectus deformity, 4.3%; limb-length inequality, 7.1%; congenital tibial dysplasia, 5.7%; hemihypertrophy, 1.4%; and plexiform neurofibromas, 25%. The orthopaedic complications can be managed, but only rarely are they cured.

Entities:  

Mesh:

Year:  1999        PMID: 10434076     DOI: 10.5435/00124635-199907000-00002

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  40 in total

1.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

Authors:  Weixi Wang; Jeffry S Nyman; Koichiro Ono; David A Stevenson; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2011-07-14       Impact factor: 6.150

2.  Neurofibromatosis type 1 with idiopathic hypercalciuria, nephrolithiasis and horseshoe kidney.

Authors:  Saliha Senel; Nilgun Erkek; Can Demir Karacan
Journal:  Pediatr Nephrol       Date:  2010-02-25       Impact factor: 3.714

3.  Not just a fracture.

Authors:  Margot Van de Vijver
Journal:  BMJ Case Rep       Date:  2014-02-05

4.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

5.  Double inactivation of NF1 in tibial pseudarthrosis.

Authors:  David A Stevenson; Holly Zhou; Shadi Ashrafi; Ludwine M Messiaen; John C Carey; Jacques L D'Astous; Stephen D Santora; David H Viskochil
Journal:  Am J Hum Genet       Date:  2006-05-10       Impact factor: 11.025

6.  Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.

Authors:  David A Stevenson; David H Viskochil; John C Carey; Xiaoming Sheng; Mary Murray; Laurie Moyer-Mileur; Judd Shelton; William L Roberts; Ashley M Bunker; Heather Hanson; Stephanie Bauer; Jacques L D'Astous
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

7.  Congenital pseudarthrosis of the tibia: the results of an evolving protocol of management.

Authors:  N Nicolaou; A Ghassemi; R A Hill
Journal:  J Child Orthop       Date:  2013-06-12       Impact factor: 1.548

8.  Epidemiology and treatment outcome of congenital pseudarthrosis of the tibia.

Authors:  Joachim Horn; Harald Steen; Terje Terjesen
Journal:  J Child Orthop       Date:  2013-01-18       Impact factor: 1.548

Review 9.  Diagnosis and treatment of osteopenic fractures in children.

Authors:  Charles T Mehlman; Marcia A Shepherd; Carie S Norris; Jessica B McCourt
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

10.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.